<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840706</url>
  </required_header>
  <id_info>
    <org_study_id>MyAirvo</org_study_id>
    <nct_id>NCT04840706</nct_id>
  </id_info>
  <brief_title>Open-Label Prospective Study Comparing Long-Term Outcome With or Without HFNC in Patients With Stable Hypercapnic COPD</brief_title>
  <acronym>MyAirvo</acronym>
  <official_title>Open-Label Prospective Study Comparing Long-Term Outcome With or Without High-flow Nasal Cannula AirvoTM in Patients With Stable Hypercapnic COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to compare long-term one-year outcome with or without AirvoTM in&#xD;
      stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation&#xD;
      of COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When compared to NIV, much less experience is available from clinical studies on HFNC&#xD;
      therapy. Until now, few studies have investigated the effect of HFNC therapy on hypercapnic&#xD;
      COPD patients and the number of patients recruited in these studies is limited. AirvoTM&#xD;
      therapy could be good choice of treatment for those COPD patients that are not compliant to&#xD;
      NIV but need treatment for hypercapnia in order to reduce COPD exacerbations and enhance&#xD;
      QOL.The aims of the study are to compare long-term one-year outcome with or without AirvoTM&#xD;
      in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute&#xD;
      exacerbation of COPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCO2</measure>
    <time_frame>1 year</time_frame>
    <description>Improvement in daytime capillary pCO2 â‰¥ 0.5 kPa in the AirvoTM group compared to the standard care group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute exacerbation rate</measure>
    <time_frame>1 year</time_frame>
    <description>decrease in acute exacerbation (moderate or severe) rate of COPD in AirvoTM group compared to the previous 12 months before entering the study and standard care group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Airvo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to use Airvo device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients not using Airvo, standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFNC Airvo</intervention_name>
    <description>HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD</description>
    <arm_group_label>Airvo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>No HFNC treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:COPD patients 1) with at least two acute moderate or severe&#xD;
        exacerbations during past 12 months, 2) who at the follow-up visit one month after an acute&#xD;
        severe exacerbation of COPD are hypercapnic (capillary pCO2 &gt;6.5 kPa) and not willing to&#xD;
        use NIV or have used it less than 4 h/d during the last month despite optimal settings&#xD;
        prescribed by an experienced pulmonologist, or if a patient at the follow-up one month&#xD;
        after a severe exacerbation is hypercapnic and is willing to try NIV (initiated at the&#xD;
        follow-up visit, not at the ward), but then uses it less than 4h/d during the following&#xD;
        month. Acute moderate (treated with short acting bronchodilators plus antibiotics and/or&#xD;
        oral corticosteroids) and severe (patient requires hospitalization or visits the emergency&#xD;
        room) exacerbations of COPD are defined according to the GINA Guidelines (GOLD 2019).&#xD;
&#xD;
        Exclusion Criteria: 1) OSA (diagnosed OSA or high suspicion OSA because of regular snoring,&#xD;
        witnessed apneas and daytime sleepiness), 2) neuromuscular or chest wall disease, 3) BMI&gt;35&#xD;
        kg/m2 or 4) a patient is not able to give his/her informed consent for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Tarja Saaresranta</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

